ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,10252
-0,02%
Bitcoin
66.968,71
1,22%
Brent Oil
84,155
0,67%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Johnson & Johnson (0R34)

  7. Johnson & Johnson (0R34) Notícias

0R34

Johnson & Johnson (0R34)

Johnson & Johnson
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:LSE:0R34
DataHoraFonteTítuloCódigoCompanhia
01/05/202410:17Alliance NewsAlliance NewsTOP NEWS: J&J proposes USD6.48 billion settlement of cancer lawsuitsLSE:0R34Johnson & Johnson
16/04/202407:54Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson upgrades guidance on swing to earningsLSE:0R34Johnson & Johnson
05/04/202408:02Alliance NewsAlliance NewsTOP NEWS: J&J swoops for Shockwave Medical in USD13.1 billion dealLSE:0R34Johnson & Johnson
25/03/202415:28Alliance NewsAlliance NewsIN BRIEF: J&J submits US premarket approval application for VaripulseLSE:0R34Johnson & Johnson
18/03/202408:10Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson receives FDA recommendation for CarvyktiLSE:0R34Johnson & Johnson
23/02/202415:32Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson gets EMA nod for Carvykti in myelomaLSE:0R34Johnson & Johnson
02/02/202403:22Alliance NewsAlliance NewsTOP NEWS: US sends drugmakers initial offers in Medicare price talksLSE:0R34Johnson & Johnson
23/01/202408:41Alliance NewsAlliance NewsTOP NEWS: Johnson & Johnson eyes future growth; 2023 sales riseLSE:0R34Johnson & Johnson
19/01/202418:34Alliance NewsAlliance NewsIN BRIEF: J&J gets US FDA approval for cancer treatment BalversaLSE:0R34Johnson & Johnson
05/12/202310:24Alliance NewsAlliance NewsTOP NEWS: J&J expects strong long-term growth in three key driversLSE:0R34Johnson & Johnson
23/10/202308:03Alliance NewsAlliance NewsJ&J report slew of positive trial results focused on various cancersLSE:0R34Johnson & Johnson
17/10/202307:46Alliance NewsAlliance NewsTOP NEWS: J&J raises full-year sales outlook after "solid" quarterLSE:0R34Johnson & Johnson
06/10/202312:52Alliance NewsAlliance NewsIN BRIEF: J&J applies for indication extension to EMA for RybrevantLSE:0R34Johnson & Johnson
03/10/202313:00Alliance NewsAlliance NewsDrugmakers agree to US government price talks amid pushbackLSE:0R34Johnson & Johnson
07/09/202302:50Alliance NewsAlliance NewsJ&J's Janssen ends Phase 3 MACiTEPH study evaluating macitentanLSE:0R34Johnson & Johnson
30/08/202313:07Alliance NewsAlliance NewsTOP NEWS: J&J forecasts strong growth in earnings after Kenvue splitLSE:0R34Johnson & Johnson
10/08/202317:34Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson's blood cancer therapy approved by FDALSE:0R34Johnson & Johnson
20/07/202308:30Alliance NewsAlliance NewsTOP NEWS: J&J ups full-year guidance after "robust" second quarterLSE:0R34Johnson & Johnson
30/05/202312:48Alliance NewsAlliance NewsJ&J seeks FDA approval for pulmonary arterial hypertension treatmentLSE:0R34Johnson & Johnson
09/05/202316:23Alliance NewsAlliance NewsJ&J says Tremfya data shows positive results for ulcerative colitisLSE:0R34Johnson & Johnson
04/05/202308:41Alliance NewsAlliance NewsIN BRIEF: J&J prices subsidiary Kenvue's NYSE initial public offeringLSE:0R34Johnson & Johnson
01/05/202303:51Alliance NewsAlliance NewsJohnson & Johnson reports first results from TAR-200 studyLSE:0R34Johnson & Johnson
18/04/202308:06Alliance NewsAlliance NewsTOP NEWS: J&J swings to first quarter loss due to litigation costsLSE:0R34Johnson & Johnson
05/04/202302:01Alliance NewsAlliance NewsJ&J proposes USD8.9 billion settlement of talc cancer claimsLSE:0R34Johnson & Johnson
04/04/202317:57Alliance NewsAlliance NewsIN BRIEF: J&J subsidiary re-files for bankruptcy amid talc claimsLSE:0R34Johnson & Johnson
17/03/202315:04Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson notes positive data for psoriasis drugLSE:0R34Johnson & Johnson
24/01/202309:33Alliance NewsAlliance NewsTOP NEWS: J&J fourth-quarter revenue falls on fewer Covid jab salesLSE:0R34Johnson & Johnson
05/01/202306:06Alliance NewsAlliance NewsJohnson & Johnson's consumer health unit files to go publicLSE:0R34Johnson & Johnson
09/12/202213:51Alliance NewsAlliance NewsIN BRIEF: Johnson & Johnson submits licence application to FDALSE:0R34Johnson & Johnson
01/12/202208:37Alliance NewsAlliance NewsJohnson & Johnson appoints Chief Executive Joaquin Duato as new chairLSE:0R34Johnson & Johnson
 Apresentando as notícias mais relevantes sobre:LSE:0R34

Seu Histórico Recente

BIT
F18806
Vontobel Financial Produ...
DGFX
HPLUSDT
HappyLand.Finance
USOTC
GRRDF
Grandvision NV (CE)
BIT
P1R0L9
BNP Paribas Issuance
TG
AVLA
Air Lease
BIT
P1GAC4
BNP Paribas Issuance
EU
CCN
Crcam Normandie-Seine
USOTC
ADMNF
Admiral Acquisition (PK)
HUOB
STRMUSDT
Stream
ASX
DGGF
BetaShares Capital
USOTC
ABLGF
Alten (PK)
USOTC
AWLID
Ameriwest Lithium (PK)
BIT
P1U548
BNP Paribas Issuance
NASDAQI
FN60GI
First North Energy GI
BIT
P1RX95
BNP Paribas Issuance
USOTC
GTHDF
Genesis Technology (PK)
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados